Jump to main content
Jump to site search

Issue 1, 2012
Previous Article Next Article

Polyamine-based small molecule epigenetic modulators

Author affiliations

Abstract

Chromatin remodelling enzymes such as the histone deacetylases (HDACs) and histone demethylases such as lysine-specific demethylase 1 (LSD1) have been validated as targets for cancer drug discovery. Although a number of HDACinhibitors have been marketed or are in human clinical trials, the search for isoform-specific HDACinhibitors is an ongoing effort. In addition, the discovery and development of compounds targeting histone demethylases are in their early stages. Epigenetic modulators used in combination with traditional antitumor agents such as 5-azacytidine represent an exciting new approach to cancer chemotherapy. We have developed multiple series of HDACinhibitors and LSD1inhibitors that promote the re-expression of aberrantly silenced genes that are important in human cancer. The design, synthesis and biological activity of these analogues is described herein.

Graphical abstract: Polyamine-based small molecule epigenetic modulators

  • This article is part of the themed collection: Epigenetics
Back to tab navigation

Publication details

The article was received on 26 Aug 2011, accepted on 26 Sep 2011 and first published on 25 Oct 2011


Article type: Review Article
DOI: 10.1039/C1MD00220A
Med. Chem. Commun., 2012,3, 14-21

  •   Request permissions

    Polyamine-based small molecule epigenetic modulators

    S. K. Sharma, S. Hazeldine, M. L. Crowley, A. Hanson, R. Beattie, S. Varghese, T. M. D. Senanayake, A. Hirata, F. Hirata, Y. Huang, Y. Wu, N. Steinbergs, T. Murray-Stewart, I. Bytheway, R. A. Casero and P. M. Woster, Med. Chem. Commun., 2012, 3, 14
    DOI: 10.1039/C1MD00220A

Search articles by author

Spotlight

Advertisements